KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Other Accumulated Expenses (2017 - 2020)

Historic Other Accumulated Expenses for Aquestive Therapeutics (AQST) over the last 4 years, with Q4 2020 value amounting to $201000.0.

  • Aquestive Therapeutics' Other Accumulated Expenses fell 1728.4% to $201000.0 in Q4 2020 from the same period last year, while for Dec 2020 it was $201000.0, marking a year-over-year decrease of 1728.4%. This contributed to the annual value of $201000.0 for FY2020, which is 1728.4% down from last year.
  • Latest data reveals that Aquestive Therapeutics reported Other Accumulated Expenses of $201000.0 as of Q4 2020, which was down 1728.4% from $284000.0 recorded in Q3 2020.
  • In the past 5 years, Aquestive Therapeutics' Other Accumulated Expenses ranged from a high of $284000.0 in Q3 2020 and a low of $97000.0 during Q1 2020
  • In the last 4 years, Aquestive Therapeutics' Other Accumulated Expenses had a median value of $215000.0 in 2018 and averaged $213916.7.
  • Data for Aquestive Therapeutics' Other Accumulated Expenses shows a peak YoY increase of 5434.78% (in 2020) and a maximum YoY decrease of 4947.92% (in 2020) over the last 5 years.
  • Over the past 4 years, Aquestive Therapeutics' Other Accumulated Expenses (Quarter) stood at $225000.0 in 2017, then fell by 8.0% to $207000.0 in 2018, then grew by 17.39% to $243000.0 in 2019, then fell by 17.28% to $201000.0 in 2020.
  • Its Other Accumulated Expenses was $201000.0 in Q4 2020, compared to $284000.0 in Q3 2020 and $223000.0 in Q2 2020.